UBS AM’s Cidara Therapeutics CDTX Stock Holding History

UBS AM’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,219	Closed	-$4.47M	–	3818
2025 Q4	$4.47M	Buy	20,219 +7,319	+57%	+$1.18M	﹤0.01%	1516
2025 Q3	$1.24M	Buy	+12,900	New	+$823K	﹤0.01%	1940
2021 Q3	–	Sell	-146	Closed	-$5.91K	–	2750
2021 Q2	$5.91K	Buy	+146	New	+$6.18K	﹤0.01%	2748

UBS AM's CDTX Position: Q1 2026 in Review

UBS AM sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 20,219 shares — an estimated $4.47M sold.

UBS AM first reported a position in CDTX in Q2 2021 and held it in 3 quarters. The position peaked at $4.47M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

UBS AM reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
UBS AM sold 20,219 Cidara Therapeutics shares in Q1 2026, an estimated $4.47M.
UBS AM first reported a position in Cidara Therapeutics in Q2 2021 and held it in 3 quarters.
UBS AM's Cidara Therapeutics position peaked at $4.47M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.